Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-08-02
2011-08-02
Swope, Sheridan (Department: 1652)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S350000
Reexamination Certificate
active
07989606
ABSTRACT:
The present invention relates to novel nucleic acids which encode novel mutant forms of Inhibitor Protein-1 (1-1). In particular, the 1-1 mutant forms comprise altered phosphorylation sites of PKC-α. In addition, the present invention relates to methods of regulating cardiac contractility and function, and for treatment of cardio myopathy and heart failure, which employ the novel nucleic acids and polypeptides. Vectors comprising the novel nucleic acids, Antibodies to the novel proteins, and diagnostic and screening methods associated therewith, are also provided.
REFERENCES:
patent: 2002/0159978 (2002-10-01), Allen
patent: 2004/0214760 (2004-10-01), Gupta et al.
patent: WO-02056837 (2002-07-01), None
Rodriguez et al, Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem. Dec. 15, 2006;281(50):38599-608. Epub Oct. 17, 2006.
EP07750317—SuppSearchReport. Apr. 6, 2009.
Pathak et al, Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. Apr. 15, 2005;96(7):756-66. Epub Mar. 3, 2005.
International Search Report (PCT/ISA/210), May 23, 2008, Kranias; WO/07/100465.
Written Opinion of the International Searching Authority (PCT/ISA/237), May 23, 2008, Kranias; WO/07/100465.
Endo et al, Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Biochemistry. Apr. 23, 1996, vol. 35, No. 16, pp. 5220-5228.
Nicolaou, P. et al., “Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology”, Journal of Molecular and Cellular Cardiology, Academic Press, GB, vol. 47, No. 3, Sep. 1, 2009, pp. 365-371.
Pathak, A., et al., “Enhancement of cardiac function and supression of heart failure progression by inhibition of protein phosphatase 1”, Circulation Research, Apr. 15, 2005, pp. 756-766.
Pathak, A., et al., “Therapeutic targeting of the type 1 phosphatase activity in murine models of cardiomyopathy”, Circulation, Lippincott Williams & Wilkins, US, vol. 110, No. 17, Suppl., Oct. 1, 2004, p. 22.
Carr, A. N., et al., “Type 1 phosphatase, a negative regulator of cardiac function”, Molecular and Cellular Biology, Jun. 2002, LNKD-PUBMED: 12024026, vol. 22, No. 12, pp. 4124-4135.
Pathak, A., et al., “Targeted inhibition of protein phosphatase 1 via expression of the constitutively active inhibitor-1 protein: A novel molecular inotrope”, Circulation, Lippincott Williams & Wilkins, US, vol. 108, No. 17, Suppl., Oct. 28, 2003, pp. IV-124.
Nicolaou, P., et al., “Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury”, Circulation Research, Apr. 24, 2009, pp. 1012-1020.
F. Del Monte et al., “Topical Review—Targeting Calcium Cycling Proteins in Heart Failure Through Gene Transfer”, Journal of Physiology, 2003, 546-1, pp. 49-61.
Ronen Beeri, MD, et al.;New Efficient Catheter-Based System for Myocardial Gene Delivery; Circulation; 2002; vol. 106; pp. 1756-1759.
Federica del Monte, MD, PhD, et al.;Improvement in Survival and Cardiac Metabolism After Gene Transfer of Sarcoplasmic Reticulum Ca2+-ATPase in a Rat Model of Heart Failure; Circulation; 2001; vol. 104; pp. 1424-1429.
Ulrich Gergs et al.;Overexpression of the Catalytic Subunit of Protein Phosphatase 2A Impairs Cardiac Function; The Journal of Biological Chemistry; vol. 179; No. 38; Issue of Sep. 24, 2004; pp. 40827-40834.
Yoichi Suzuki, et al;Insulin Control of Glycogen Metabolism in Knockout Mice Lacking the Muscle-Specific Protein Phosphatase PP1G/Rgl; Molecular and Cellular Biology; Apr. 2001; vol. 21; No. 8; pp. 2683-2694.
Neil Brewis, et al;Dilated cardiomyopathy in transgenic mice expressing a mutant A subunit of protein phosphatase 2A; American J. Physicol Heart Circ Physiol; vol. 279; pp. H13017-H2000.
Federica del Monte, MD, PhD et al.;Restoration of Contractile Function in Isolated Cardiomyocytes From Failing Human Heartsby Gene Transfer of SERCA2a, Circulation 1999 p. 2308-2311.
Peter Boknik, et al.;Protein phosphatase activity is increased in a rat model of long-term β-αδrenergic renergic stimulation; Naunyn-Schmiedebertg's Arch Pharmacol; 2000; vol. 362; pp. 222-231.
Michael R. Bristow, M.D., Ph.D., et al.;Decreased Catecholamine Sensitivity and β-Adrenergic-receptor-Adrenergic-receptor Density in Failing Human Hearts; The New England Journal of Medicine; Jul. 22, 1982; vol. 307; No. 4; pp. 205-211.
Philip Cohen;The Structure and Regulation of Protein Phosphatases; Advances in Second Messenger and Phosphoproten Research; vol. 24; p. 230-235.
Jeffrey D. Molkentin et al.;A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy; Cell; vol. 93; Apr. 17, 1998; pp. 215-228.
Boyu Huang, et al.;Diminished Basal Phosphorylation Level of Phospholamban in the Postinfarction Remodeled Rat Ventricle Role of β-Adrenergic Pathway, GiProtein, Phosphodiesterase, and Phosphatases; Circulation Research; vol. 85; No. 9; Oct. 29, 1999; pp. 848-855.
Jern B. Sande, et al.;Reduced level of serine16phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced DERCA2 activity; Cardiovascular research; vol. 53; No. 1; Jan. 2002; pp. 382-391.
R. C. Gupta, et al.; Suplement to Circulation; vol. 96; No. 8; Oct. 21, 1997; pp. I-361-I362.
Joachim Neumann et al.;Increased Expression of Cardiac Phosphatases in Patients with End-stage Heart Failure; J. Mol. Cell Cardiol; vol. 29; Jan. 1997; pp. 265-272.
Helen Kiriazis et al.;Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis; Cardiovascular Research; vol. 52; 2002; pp. 372-381.
Donald M. Bers;Cardiac excitation-contrction coupling; Nature; vol. 415; Jan. 10, 2002; pp. 198-205.
Andrew N. Carr et al.;Type 1 Phosphatase, a Negative Regulator of Cardiac Function; Molecular and Cellular Biology; Jun. 2002; vol. 22; No. 12; pp. 4124-4135.
Hajjar et al., “Modulation of Ventricular function through gene transfer in vitro”, PNAS 95: 5251-5256 (1998).
Blaese et al., Science 270:475-480 (1995).
Roth et al., Nature Medicine 2(9):985-991 (1996).
Khuri et al. Nature Medicine 6(8):879-885 (2000).
Cavazzana-Calvo et al., Science 288:669-672 (2000).
Kay et al., Nature Genetics 24:257-261 (2000).
Crystal, Science 270:404, 405 (1995).
Windt et al., Proc. Natl Acad Sci., 2001, 98 (6) 3322-3327.
Armouche et al., FASEB J. Jan. 2, 2003, 437-439.
Miyamoto et al., Proc Natl Acad Sci USA 2000; 97(2): 793-798.
Tai et al., Japanese Journal of Clinical Oncology 31, 217-220, 2001.
Xiao et al., Journal of Virology, 1999, 3994-4003.
Bowie et al., Science, 247: 1306-10, 1990.
Boekstegers et al., Gene Therapy, 2000, 7, 232-240.
Ponder et al., Current Opinion Hematol, 2006, 13, 301-307.
Emani et al., Mol Ther. Aug. 2003;8(2):306-13, abstract.
Church et al., Journal of Veterinary Cardiology, 2007, 9, 53-57.
Kertesz et al., Tex Heart Inst J 1997, 24, 301-307.
Kaiser, Science, 2007, 317, 580.
Schroder et al., Expert Opin Biol Ther. Sep. 2004;4(9):1413-22.
Ecke, Goodman & Gilman's The Pharmacological basis of Therapeutics, 1996, McGraw-Hill, New York, NY. pp. 77-101.
Verma et al., Annu Rev Biochem. 2005;74:711-38.
Thomas et al., Nature Rev.Genet. 4: 346-358; 2003.
Brockstedt et al., Clinical Immunol. 92:67-75; 1999.
Hajjar et al., Circ. Res., Mar. 31, 2000; 86(6): 616-621.
McTiernan et al., Gene Therapy, 2007, 14, 1613-1622.
Donahue et al., Proc. Natl Aced Sci US A. 1997;94: 4664-4668.
Sobie et al., J Clin Invest. Mar. 2003;111(6):801-3.
Hoshijima Pharmacology & Therapeutics 105 (2005) 211-228.
Holschneider et al., Int J Devl Neuroscience, 2000, 18: 615-618.
Skolnick et al., Trends in Biotech, 2000, 18, 34-39.
Supplementary European Search Report issued in EP 07 750 317.5, Apr. 6, 2009, The University fo Cincinnati.
Bibb, J.A., et al. “
Kranias Evangelia
Mitton Bryan
Rodriguez Patricia
Edwards Angell Palmer & & Dodge LLP
Lauro, Esq. Peter C.
McCool, Esq. Gabriel J.
Swope Sheridan
The University of Cincinnati
LandOfFree
Phosphatase inhibitor protein-1 as a regulator of cardiac... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphatase inhibitor protein-1 as a regulator of cardiac..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphatase inhibitor protein-1 as a regulator of cardiac... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2709192